329 related articles for article (PubMed ID: 19940355)
1. Modulation of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells.
Papanicolaou SE; Phipps RJ; Fyhrie DP; Genetos DC
Biorheology; 2009; 46(5):389-99. PubMed ID: 19940355
[TBL] [Abstract][Full Text] [Related]
2. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin.
Robling AG; Niziolek PJ; Baldridge LA; Condon KW; Allen MR; Alam I; Mantila SM; Gluhak-Heinrich J; Bellido TM; Harris SE; Turner CH
J Biol Chem; 2008 Feb; 283(9):5866-75. PubMed ID: 18089564
[TBL] [Abstract][Full Text] [Related]
3. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading.
Tu X; Rhee Y; Condon KW; Bivi N; Allen MR; Dwyer D; Stolina M; Turner CH; Robling AG; Plotkin LI; Bellido T
Bone; 2012 Jan; 50(1):209-17. PubMed ID: 22075208
[TBL] [Abstract][Full Text] [Related]
4. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo.
Choi HY; Dieckmann M; Herz J; Niemeier A
PLoS One; 2009 Nov; 4(11):e7930. PubMed ID: 19936252
[TBL] [Abstract][Full Text] [Related]
5. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity.
Ellies DL; Viviano B; McCarthy J; Rey JP; Itasaki N; Saunders S; Krumlauf R
J Bone Miner Res; 2006 Nov; 21(11):1738-49. PubMed ID: 17002572
[TBL] [Abstract][Full Text] [Related]
6. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling.
Li X; Zhang Y; Kang H; Liu W; Liu P; Zhang J; Harris SE; Wu D
J Biol Chem; 2005 May; 280(20):19883-7. PubMed ID: 15778503
[TBL] [Abstract][Full Text] [Related]
7. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis.
Bellido T; Ali AA; Gubrij I; Plotkin LI; Fu Q; O'Brien CA; Manolagas SC; Jilka RL
Endocrinology; 2005 Nov; 146(11):4577-83. PubMed ID: 16081646
[TBL] [Abstract][Full Text] [Related]
8. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling.
Rhee Y; Allen MR; Condon K; Lezcano V; Ronda AC; Galli C; Olivos N; Passeri G; O'Brien CA; Bivi N; Plotkin LI; Bellido T
J Bone Miner Res; 2011 May; 26(5):1035-46. PubMed ID: 21140374
[TBL] [Abstract][Full Text] [Related]
9. Exendin-4 increases bone mineral density in type 2 diabetic OLETF rats potentially through the down-regulation of SOST/sclerostin in osteocytes.
Kim JY; Lee SK; Jo KJ; Song DY; Lim DM; Park KY; Bonewald LF; Kim BJ
Life Sci; 2013 Mar; 92(10):533-40. PubMed ID: 23357248
[TBL] [Abstract][Full Text] [Related]
10. BMP signaling negatively regulates bone mass through sclerostin by inhibiting the canonical Wnt pathway.
Kamiya N; Ye L; Kobayashi T; Mochida Y; Yamauchi M; Kronenberg HM; Feng JQ; Mishina Y
Development; 2008 Nov; 135(22):3801-11. PubMed ID: 18927151
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation contributes to the regulation of sclerostin expression in human osteocytes.
Delgado-Calle J; Sañudo C; Bolado A; Fernández AF; Arozamena J; Pascual-Carra MA; Rodriguez-Rey JC; Fraga MF; Bonewald L; Riancho JA
J Bone Miner Res; 2012 Apr; 27(4):926-37. PubMed ID: 22162201
[TBL] [Abstract][Full Text] [Related]
12. Sclerostin regulates release of bone mineral by osteocytes by induction of carbonic anhydrase 2.
Kogawa M; Wijenayaka AR; Ormsby RT; Thomas GP; Anderson PH; Bonewald LF; Findlay DM; Atkins GJ
J Bone Miner Res; 2013 Dec; 28(12):2436-48. PubMed ID: 23737439
[TBL] [Abstract][Full Text] [Related]
13. The Wnt Inhibitor Sclerostin Is Up-regulated by Mechanical Unloading in Osteocytes in Vitro.
Spatz JM; Wein MN; Gooi JH; Qu Y; Garr JL; Liu S; Barry KJ; Uda Y; Lai F; Dedic C; Balcells-Camps M; Kronenberg HM; Babij P; Pajevic PD
J Biol Chem; 2015 Jul; 290(27):16744-58. PubMed ID: 25953900
[TBL] [Abstract][Full Text] [Related]
14. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins.
Winkler DG; Sutherland MS; Ojala E; Turcott E; Geoghegan JC; Shpektor D; Skonier JE; Yu C; Latham JA
J Biol Chem; 2005 Jan; 280(4):2498-502. PubMed ID: 15545262
[TBL] [Abstract][Full Text] [Related]
15. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway.
Wijenayaka AR; Kogawa M; Lim HP; Bonewald LF; Findlay DM; Atkins GJ
PLoS One; 2011; 6(10):e25900. PubMed ID: 21991382
[TBL] [Abstract][Full Text] [Related]
16. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.
Kamiya N; Kobayashi T; Mochida Y; Yu PB; Yamauchi M; Kronenberg HM; Mishina Y
J Bone Miner Res; 2010 Feb; 25(2):200-10. PubMed ID: 19874086
[TBL] [Abstract][Full Text] [Related]
17. Sclerostin is a locally acting regulator of late-osteoblast/preosteocyte differentiation and regulates mineralization through a MEPE-ASARM-dependent mechanism.
Atkins GJ; Rowe PS; Lim HP; Welldon KJ; Ormsby R; Wijenayaka AR; Zelenchuk L; Evdokiou A; Findlay DM
J Bone Miner Res; 2011 Jul; 26(7):1425-36. PubMed ID: 21312267
[TBL] [Abstract][Full Text] [Related]
18. CYR61/CCN1 Regulates Sclerostin Levels and Bone Maintenance.
Zhao G; Huang BL; Rigueur D; Wang W; Bhoot C; Charles KR; Baek J; Mohan S; Jiang J; Lyons KM
J Bone Miner Res; 2018 Jun; 33(6):1076-1089. PubMed ID: 29351359
[TBL] [Abstract][Full Text] [Related]
19. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement.
Shu R; Bai D; Sheu T; He Y; Yang X; Xue C; He Y; Zhao M; Han X
PLoS One; 2017; 12(1):e0167312. PubMed ID: 28081119
[TBL] [Abstract][Full Text] [Related]
20. Sclerostin is a novel secreted osteoclast-derived bone morphogenetic protein antagonist with unique ligand specificity.
Kusu N; Laurikkala J; Imanishi M; Usui H; Konishi M; Miyake A; Thesleff I; Itoh N
J Biol Chem; 2003 Jun; 278(26):24113-7. PubMed ID: 12702725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
